Akso Health Group
Akso Health Group's revenue fell 6.4% to $14 million in fiscal 2026. Its operating margin was −149.7%, up from −1,125.4% a year earlier. Free cash flow was −$13 million, against $1 million a year earlier. The diluted share count rose 153.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
From fiscal 2017 to 2019, earnings per share fell 29.3% a year and net income 20.0% a year, as new shares raised the share count by 25% and diluted each share's earnings. Akso Health Group then lost money in fiscal 2020, 2021, 2022, 2023, 2024, 2025 and 2026.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 18 | 8 | 85 | 176 | 0 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −4.0x | −42.4x | −77.4x | — | — |
| Current ratio | 1.2x | 1.8x | 39.5x | 14.2x | 21.8x |
| Quick ratio | 1.1x | 1.6x | 39.5x | 14.2x | 21.7x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | 519.0% | −98.9% |
| Altman Z'' | 44.96 | 10.58 | 23.59 |
| Accruals ratio | −13.3% | −76.3% | −2.9% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Akso Health Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Akso Health Group | FY26 | −6.4% | −149.7% | −92.5% | — | — | — | |
| DataMeds AI | FY25 | 28.7% | −401.7% | — | −369.5% | — | 3 | Compare |
| Quanome Technologies | FY26 | 111.8% | −174.2% | −54.5% | — | — | — | Compare |
| Cosmos Health | FY25 | 19.9% | −25.6% | −13.0% | −53.0% | — | 5 | Compare |
| Accendra Health | FY25 | 3.1% | 1.0% | −10.6% | 1.2% | 7.3x | 2 | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 23 | 107 | 4 | 7 | 2 | 6 | 13 | 2 | 15 | 14 |
| Revenue growth | — | 368.0% | −96.5% | 87.1% | −74.6% | 241.9% | 119.7% | −81.7% | 512.1% | −6.4% |
| Gross profit | 23 | 107 | −4 | 7 | 2 | 1 | 1 | 0 | −0 | −0 |
| Research and development | 2 | 3 | 0 | 0 | 0 | 0 | — | — | — | — |
| Operating income | 10 | 76 | −7 | −48 | −4 | −3 | −14 | −9 | −166 | −21 |
| Net income | 9 | 66 | 6 | −71 | −35 | −17 | −1 | −10 | −135 | −19 |
| Diluted EPS (US$) | 0.20 | 1.37 | 0.10 | −1.46 | −0.71 | −0.28 | −0.02 | — | — | 0.01 |
| Diluted shares (millions) | 42 | 48 | 53 | 49 | 49 | 60 | 69 | 142 | 855 | 2,168 |
| Cash flow | ||||||||||
| Cash from operations | 8 | 88 | −2 | −58 | 10 | −9 | −3 | 1 | 1 | −13 |
| Capital expenditure | 0 | 0 | 0 | 0 | — | 0 | — | — | 0 | 0 |
| Free cash flow | 8 | 87 | −2 | −58 | — | −9 | — | — | 1 | −13 |
| Dividends paid | 0 | 0 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 56 | 94 | 0 |
| Stock-based compensation | 0 | 2 | 7 | 0 | 0 | 0 | — | — | — | — |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 19 | 133 | 57 | 7 | 15 | 18 | 8 | 85 | 176 | 0 |
| Debt incl. finance leases | — | — | 20 | 20 | — | — | — | — | — | — |
| Total assets | 28 | 164 | 173 | 80 | 32 | 63 | 20 | 142 | 215 | 190 |
| Total liabilities | 5 | 24 | 47 | 32 | 14 | 50 | 12 | 4 | 16 | 9 |
| Shareholders' equity | 24 | 140 | 126 | 48 | 17 | 12 | 9 | 138 | 199 | 181 |
| Margins and ratios | ||||||||||
| Gross margin | 100.0% | 100.0% | −100.2% | 100.0% | 100.0% | 10.1% | 9.6% | 5.1% | −1.9% | −0.1% |
| Operating margin | 43.2% | 70.7% | −194.6% | −695.7% | −241.7% | −54.3% | −108.2% | −357.8% | −1,125.4% | −149.7% |
| Net margin | 37.4% | 61.0% | 149.7% | −1,029.7% | −1,984.5% | −280.9% | −10.3% | −391.8% | −913.4% | −135.0% |
| Free cash flow margin | 34.5% | 81.4% | −47.0% | −845.8% | — | −143.9% | — | — | 6.9% | −92.5% |
| Rule of 40 (growth + FCF margin) | — | 449.3% | −143.6% | −758.6% | — | 98.0% | — | — | 519.0% | −98.9% |
| Return on capital | — | — | — | −50.5% | — | — | — | — | — | — |
| Return on equity | — | 80.1% | 4.2% | −81.5% | −106.5% | −114.0% | −12.9% | −12.9% | −80.0% | −9.8% |
| Return on assets | — | 68.1% | 3.3% | −56.1% | −62.1% | −35.7% | −3.3% | −11.6% | −75.6% | −9.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |